AGC Biologics today announced it is adding viral vector suspension technology and capacity for the development and manufacturing of gene therapies at its commercial-grade campus in Longmont, Col., USA. These new capabilities, which begin coming online in the third quarter of 2022, complement the campus’ adherent viral vector and cell therapy offerings – enabling AGC Biologics to provide an in-depth variety of end-to-end cell and gene therapy services at this site.
AGC Biologics is deeply concerned and grieved about the situation in Ukraine. We sincerely hope that peaceful life will return to everyone as soon as possible. We also stand in partnership with our parent company, AGC Inc., in providing support for the safety and wellbeing of our Ukrainian colleagues and their families.
AGC Biologics today announced Whitney Sandberg has been appointed as the company’s Vice President for Quality in Colorado. In this position she will have executive oversight for quality operations at the company’s two facilities in the state, located in Boulder and Longmont. Both facilities provide AGC Biologics critical resources for serving its global clientele, and Sandberg’s expertise will ensure each location produces products of the highest quality that meet global GMP requirements and industry expectations.
AGC Biologics today announced it won the 2021 Transatlantic Award from the American Chamber of Commerce in Italy (AmCham). The company was named the 2021 winner for its investments in the Italian biopharmaceutical industry, which includes expansion at its Center of Excellence in Milan to make it a global hub for cell and gene therapy innovation, development and manufacturing.
AGC Biologics to produce Procizumab for early and late clinical Phases at the company’s Chiba and Copenhagen facilities